{"entity":{"id":"nct05821686","kind":"trial","name":"Efficacy of Interleukin-2 in Triple Negative Breast Cancer","aka":[],"tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Nova Scotia Health Authority, not yet recruiting.","summary":"Efficacy of Interleukin-2 in Triple Negative Breast Cancer is a phase 1/2, interventional study registered as NCT05821686 by Nova Scotia Health Authority, with a registry enrolment figure of 10 participants, started 2026-01-02 and due to reach its primary completion in 2028-04. Interventions recorded: Human Interleukin-2 (IL-2) (Proleukin). Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Women with biopsy proven TNBC who are not scheduled to receive neoadjuvant chemotherapy\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05821686","url":"https://clinicaltrials.gov/study/NCT05821686"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05821686","phase":"1/2","setting":"Efficacy of Intralesional IL-2 for Resectable Triple Negative Breast Cancer","sponsor":"Nova Scotia Health Authority","enrolled":10,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05821686/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}